Review of NICE Technology Appraisal Guidance No 86, on the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours

Proposal to proceed with review

The planned date for review of the above guidance was October 2007. However following consultee advice, the Institute has decided to consult on proposals earlier than originally planned. The Institute has carried out a search for information relevant to this appraisal, and believes that it is appropriate for the review to go ahead. In order to be completely confident that this is appropriate, we are asking all original consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.

Please note all comments received will be published on the Institute’s website when a decision has been taken.

Please see the list below of the organisations we have contacted.

• Association of Upper GI Surgeons
• British Association of Surgical Oncology
• British National Formulary
• British Oncological Association
• Cancer Networks Pharmacists Forum
• British Society of Gastroenterology
• Cancer Research UK
• Cancerbackup
• Department of Health
• CORE
• Institute of Cancer Research
• Macmillan Cancer Relief
• Marie Curie Cancer Care
• MRC Clinical Trials Unit, Cancer Division
• National Cancer Alliance 
• National Cancer Research Institute
• National Collaborating Centre for Cancer
• National Coordinating Centre for Health Technology Assessment National Council for Palliative Care
• NHS Confederation
• NHS Purchasing and Supplies Agency
• NHS Quality Improvement Scotland
• Novartis Pharmaceuticals UK Ltd
• Royal College of Nursing
• Royal College of Pathologists
• Royal College of Physicians
• Royal College of Radiologists
• Royal College of Surgeons
• Royal Pharmaceutical Society of Great Britain
• Sarcoma UK
• Tenovus Cancer Information Centre
• Welsh Assembly Government

17 October 2006